Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange. In response to one viewer looking for his outlook on Tesla (TSLA), Cramer says it can be considered a 'cold stock,' which means it can go higher based upon the fact alone that people like its cars. Cramer says he doesn't get in front of cold stocks -- and won't tell people whether to buy them or sell them. Over in biotech, one viewer asks whether he should go for Celgene (CELG) or Biogen (BIIB), which Cramer says is a really difficult call. He notes that Biogen has what he call an 'incredible' Alzheimer's formulation coming down, while Celgene has done great 'blocking and tackling.' The more conservative on an earnings basis is Celgene, according to Cramer, while Biogen is the one to go for if you're looking for more of a speculative play off of its next drug. Cramer tells another viewer that his opinion on Jarden (JAH) has not changed, and he likes the stock very much. As people are spending money on their homes, Jarden is well-positioned as it has what Cramer calls 'the best housewares.' Tweet your stock questions @jimcramer using #CramerQ.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.